| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Dornier MedTech, a wholly-owned subsidiary of Accuron Medical Technology group with manufacturing headquarters in Munich, Germany, is a medical device company known for its pioneering technologies and revolutionary therapies in urology. Dornier MedTech soars thanks to its deep rooted spirit of entrepreneurship, excellence and innovation while developing some of the highest quality urology products on the market today.
Biotechnology Council of New Jersey, Inc. is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Helping all patients feel known and heard when they need it most. Docent Health`s mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.
Picwell is a Philadelphia-based, healthcare technology company providing leading enterprise solutions to enhance healthcare benefits and improve the consumer experience. Picwell`s flagship offering is a SaaS-based decision support product that uses artificial intelligence to match individuals to the right health benefits during enrollment by predicting future care considerations, estimating out-of-pocket expenses, and accounting for individual preferences. Other solutions support consumerism and high-deductible health plan adoption, consumer engagement, and risk management. We are on a mission to transform choice in healthcare. More than 200 million people choose benefits each year, but the complexity of the healthcare system makes it challenging to get the right protection based on individual care and cost needs. We imagine a future where healthcare benefits are simple – and people can make the right choice with confidence.